NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Rheumatoid Arthritis
Date of first enrollment	19/05/2010
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : LY2127399 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : 30mg / 120mg LY2127399 Administered subcutaneously every 4 weeks for 48 weeks

Outcome(s)

Primary Outcome
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	Not applicable
Age maximum	Not applicable
Gender	Both
Include criteria	-Have given written informed consent -Women must not be pregnant, breastfeeding or be at risk to become pregnant during study participation
Exclude criteria	-Have had any safety event during the study for LY2127399 that patients participated in previous -Have received, during previous study, any drugs prohibited in the study protocol which includes unapproved drugs, live vaccines, or any biologic or non-biologic DMARD except for MTX, hydroxychloroquine, sulfasalazine or bucillamine